coronary artery calcification in women of the Kronos Early Estrogen Prevention Study Genetic polymorphisms associated with carotid artery intima-media thickness and

[1]  W. Dupont,et al.  Genomic DNA analysis of the estrogen receptor gene in breast cancer , 1989, Breast Cancer Research and Treatment.

[2]  K. Heimdal,et al.  Oestrogen receptor (ESR) polymorphisms and breast cancer susceptibility , 1994, Human Genetics.

[3]  R. Schmutzler,et al.  An estrogen receptor genetic polymorphism and a history of spontaneous abortion — Correlation in women with estrogen receptor positive breast cancer but not in women with estrogen receptor negative breast cancer or in women without cancer , 2004, Breast Cancer Research and Treatment.

[4]  A. LaCroix,et al.  Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women. , 2001, JAMA.

[5]  P. Bray,et al.  The PlA polymorphism of glycoprotein IIIa functions as a modifier for the effect of estrogen on platelet aggregation. , 2001, Archives of pathology & laboratory medicine.

[6]  F. Speizer,et al.  A Prospective, Observational Study of Postmenopausal Hormone Therapy and Primary Prevention of Cardiovascular Disease , 2000, Annals of Internal Medicine.

[7]  L. Clark,et al.  Meta-analysis of the association of platelet glycoprotein IIIa PlA1/A2 polymorphism with myocardial infarction. , 2000, The American journal of cardiology.

[8]  M. Perola,et al.  Glycoprotein IIIa PlA1/A2 polymorphism and sudden cardiac death , 2000 .

[9]  D. Herrington,et al.  Cardiovascular implications of the factor V Leiden mutation. , 2000, American heart journal.

[10]  R. Recker,et al.  Association of estrogen receptor-alpha genotypes with body mass index in normal healthy postmenopausal Caucasian women. , 2000, The Journal of clinical endocrinology and metabolism.

[11]  G. Knatterud,et al.  Early risks of hormone therapy in patients with coronary heart disease. , 2000, JAMA.

[12]  S. Chanprasertyothin,et al.  Oestrogen‐receptor‐α gene polymorphism affects response in bone mineral density to oestrogen in post‐menopausal women , 2000 .

[13]  M. Uchiyama,et al.  Association of serum low‐density lipoprotein metabolism with oestrogen receptor gene polymorphisms in healthy children , 2000, Acta paediatrica.

[14]  C. Glueck,et al.  Effect of exogenous estrogen on atherothrombotic vascular disease risk related to the presence or absence of the factor V Leiden mutation (resistance to activated protein C). , 1999, The American journal of cardiology.

[15]  A. Gardemann,et al.  The 4G4G Genotype of the Plasminogen Activator Inhibitor 4G/5G Gene Polymorphism Is Associated with Coronary Atherosclerosis in Patients at High Risk for this Disease , 1999, Thrombosis and Haemostasis.

[16]  E. Barrett-Connor,et al.  Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. , 1999, Circulation.

[17]  J. Manson,et al.  Hormone replacement therapy and increased plasma concentration of C-reactive protein. , 1999, Circulation.

[18]  M. Margaglione,et al.  Inherited prothrombotic conditions and premature ischemic stroke: sex difference in the association with factor V Leiden. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[19]  Y. K. Hodges,et al.  Variant estrogen and progesterone receptor messages in human vascular smooth muscle. , 1999, Circulation.

[20]  V. Beral,et al.  Hormone replacement therapy for secondary prevention of coronary heart disease. , 1999, JAMA.

[21]  S. Chaturvedi,et al.  Protein S Deficiency, Activated Protein C Resistance and Sticky Platelet Syndrome in a Young Woman with Bilateral Strokes , 1999, Cerebrovascular Diseases.

[22]  R. Cannon,et al.  Relation of fibrinolytic potentiation by estrogen to coagulation pathway activation in postmenopausal women. , 1999, The American journal of cardiology.

[23]  I. Han,et al.  Non-association of Estrogen Receptor Genotypes with Bone Mineral Density and Bone Turnover in Korean Pre-, Peri-, and Postmenopausal Women , 1999, Osteoporosis International.

[24]  Mark L. Johnson,et al.  Change of bone mass in postmenopausal Caucasian women with and without hormone replacement therapy is associated with vitamin D receptor and estrogen receptor genotypes , 1998, Human Genetics.

[25]  K. Isaaz,et al.  Prevalence of factor V Leiden (APCR) and other inherited thrombophilias in young patients with myocardial infarction and normal coronary arteries , 1998, Heart.

[26]  L. Peltonen,et al.  Array-based multiplex analysis of candidate genes reveals two independent and additive genetic risk factors for myocardial infarction in the Finnish population. , 1998, Human molecular genetics.

[27]  E. Vittinghoff,et al.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. , 1998, JAMA.

[28]  M. Makaroun,et al.  Arterial thromboembolic events in patients with the factor V Leiden mutation. , 1998, American journal of surgery.

[29]  J. Mant,et al.  Risk of myocardial infarction, angina and stroke in users of oral contraceptives: an updated analysis of a cohort study , 1998, British journal of obstetrics and gynaecology.

[30]  C. Mamotte,et al.  PIa1/a2 polymorphism of glycoprotein IIIa and risk of coronary artery disease and restenosis following coronary angioplasty. , 1998, The American journal of cardiology.

[31]  E. Oger,et al.  Prevalence of 20210 A Allele of the Prothrombin Gene in Venous Thromboembolism Patients , 1998, Thrombosis and Haemostasis.

[32]  E. Sacchi,et al.  High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. , 1998, The New England journal of medicine.

[33]  G. Dolan,et al.  Prothrombin 20210A Polymorphism and Third Generation Oral Contraceptives – A Case Report of Coeliac Axis Thrombosis and Splenic Infarction , 1998, Thrombosis and Haemostasis.

[34]  P. Chiusolo,et al.  Prothrombin G20210A mutant genotype is a risk factor for cerebrovascular ischemic disease in young patients. , 1998, Blood.

[35]  L. Kuller,et al.  Factor V Leiden Is not a Risk Factor for Arterial Vascular Disease in the Elderly: Results from the Cardiovascular Health Study , 1998, Thrombosis and Haemostasis.

[36]  J. Corral,et al.  Genetic polymorphisms of factor VII are not associated with arterial thrombosis , 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[37]  F R Rosendaal,et al.  Risk of Myocardial Infarction Associated With Factor V Leiden or Prothrombin Interaction of Coagulation Defects and Cardiovascular Risk Factors : Increased , 1998 .

[38]  S. Ehrenforth,et al.  The prothrombin 20210 A allele is frequently coinherited in young carriers of the factor V Arg 506 to Gln mutation with venous thrombophilia. , 1998, Blood.

[39]  P. Svensson,et al.  The A20210 allele of the prothrombin gene is frequently associated with the factor V Arg 506 to Gln mutation but not with protein S deficiency in thrombophilic families. , 1998, Blood.

[40]  R. Schmidt,et al.  β-Fibrinogen Gene Polymorphism (C148→T) Is Associated With Carotid Atherosclerosis , 1998 .

[41]  T. Raghunathan,et al.  Risk of stroke in young women and two prothrombotic mutations: factor V Leiden and prothrombin gene variant (G20210A) , 1998, Stroke.

[42]  P. de Knijff,et al.  Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction. , 1998, The New England journal of medicine.

[43]  B. Trudinger,et al.  Changes of Resistance to Activated Protein C in The Course of Pregnancy and Prevalence of Factor V Mutation , 1997, The Australian & New Zealand journal of obstetrics & gynaecology.

[44]  V. Arruda,et al.  Prevalence of the prothrombin gene variant 20210 G --> A among patients with myocardial infarction. , 1998, Cardiovascular research.

[45]  D. Knook,et al.  The Risk of Mortality and the Factor V Leiden Mutation in a Population-based Cohort , 1998, Thrombosis and Haemostasis.

[46]  K. Korach,et al.  Premature coronary artery disease associated with a disruptive mutation in the estrogen receptor gene in a man. , 1997, Circulation.

[47]  T. Zama,et al.  Genotype distribution of estrogen receptor polymorphisms in men and postmenopausal women from healthy and coronary populations and its relation to serum lipid levels. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[48]  K. Kario,et al.  Factor VII R353Q polymorphism and lacunar stroke in Japanese hypertensive patients and normotensive controls. , 1997, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[49]  C. Glueck,et al.  Heterozygosity for the Leiden mutation of the factor V gene, a common pathoetiology for osteonecrosis of the jaw, with thrombophilia augmented by exogenous estrogens. , 1997, The Journal of laboratory and clinical medicine.

[50]  P. de Knijff,et al.  Factor VII polymorphisms in populations with different risks of cardiovascular disease. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[51]  K. Huber,et al.  Increased prevalence of a polymorphism in the gene coding for human prothrombin in patients with coronary heart disease. , 1997, Thrombosis research.

[52]  B. Dahlbäck,et al.  The 20210 A Allele of the Prothrombin Gene Is a Common Risk Factor among Swedish Outpatients with Verified Deep Venous Thrombosis , 1997, Thrombosis and Haemostasis.

[53]  P. Ridker,et al.  Alu-repeat polymorphism in the gene coding for tissue-type plasminogen activator (t-PA) and risks of myocardial infarction among middle-aged men. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[54]  F. Rosendaal,et al.  Thrombosis in the Young: Epidemiology and Risk Factors. A Focus on Venous Thrombosis , 1997, Thrombosis and Haemostasis.

[55]  D. Dorfman,et al.  Impact of activated protein C resistance on general vascular surgical patients. , 1997, Journal of vascular surgery.

[56]  D. Arveiler,et al.  The Leu33/Pro Polymorphism (PIA1/PIA2 ) of the Glycoprotein IIIa (GPIIIa) Receptor Is Not Related to Myocardial Infarction in the ECTIM Study , 1997, Thrombosis and Haemostasis.

[57]  M. Marmot,et al.  Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study , 1997, The Lancet.

[58]  C. Shapira,et al.  Activated protein C resistance (factor V Leiden) associated with thrombosis in pregnancy , 1997, American journal of obstetrics and gynecology.

[59]  P. Ridker,et al.  Age-Specific Incidence Rates of Venous Thromboembolism among Heterozygous Carriers of Factor V Leiden Mutation , 1997, Annals of Internal Medicine.

[60]  P. Reitsma,et al.  A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. , 1996, Blood.

[61]  J. Carson,et al.  Risk of venous thromboembolism in users of hormone replacement therapy , 1996, The Lancet.

[62]  K. Newton,et al.  Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens , 1996, The Lancet.

[63]  A. Hofman,et al.  Reduced Response to Activated Protein C Is Associated with Increased Risk for Cerebrovascular Disease , 1996, Annals of Internal Medicine.

[64]  S. Goldhaber,et al.  Pulmonary embolism and deep venous thrombosis during pregnancy or oral contraceptive use: prevalence of factor V Leiden. , 1996, American heart journal.

[65]  J. Weiss,et al.  A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. , 1996, The New England journal of medicine.

[66]  Y. Ouchi,et al.  Association of bone mineral density with polymorphism of the estrogen receptor gene , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[67]  D. Arveiler,et al.  Factor VII Arg/Gln353 polymorphism determines factor VII coagulant activity in patients with myocardial infarction (MI) and control subjects in Belfast and in France but is not a strong indicator of MI risk in the ECTIM study. , 1996, Atherosclerosis.

[68]  M. Blombäck,et al.  Arg506–Gln mutation in factor V and risk of thrombosis during pregnancy , 1996, British journal of haematology.

[69]  Y. Ouchi,et al.  Association of estrogen receptor dinucleotide repeat polymorphism with osteoporosis. , 1995, Biochemical and biophysical research communications.

[70]  P. Ridker,et al.  Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. , 1995, Circulation.

[71]  S. Humphries,et al.  The 4G/5G Genetic Polymorphism in the Promoter of the Plasminogen Activator Inhibitor-1 (PAI-1) Gene Is Associated with Differences in Plasma PAI-1 Activity but not with Risk of Myocardial Infarction in the ECTIM Study , 1995, Thrombosis and Haemostasis.

[72]  P. Grant,et al.  Environmental and Genetic Factors in Relation to Elevated Circulating Levels of Plasminogen Activator Inhibitor-1 in Caucasian Patients with Non-Insulin-Dependent Diabetes Mellitus , 1995, Thrombosis and Haemostasis.

[73]  H. Arnesen,et al.  Activated protein C resistance and graft occlusion after coronary artery bypass surgery. , 1995, Thrombosis research.

[74]  B. Dahlbäck,et al.  Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. , 1995, American journal of obstetrics and gynecology.

[75]  J. Barrett,et al.  Factor V Leiden gene mutation and thrombin generation in relation to the development of acute stroke. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[76]  M. Kaste,et al.  Arg506GIn Factor V Mutation (Factor V Leiden) in Patients with Ischaemic Cerebrovascular Disease and Survivors of Myocardial Infarction , 1995, Thrombosis and Haemostasis.

[77]  A. Hamsten,et al.  Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[78]  S. Lehrer,et al.  Re: "Risk of miscarriage and a common variant of the estrogen receptor gene". , 1994, American Journal of Epidemiology.

[79]  S. Lehrer,et al.  An estrogen receptor genetic polymorphism and the risk of primary and secondary recurrent spontaneous abortion. , 1994, American journal of obstetrics and gynecology.

[80]  P. Reitsma,et al.  Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation , 1994, The Lancet.

[81]  K. Korach,et al.  Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. , 1994, The New England journal of medicine.

[82]  S. Humphries,et al.  Factor VII coagulant activity and antigen levels in healthy men are determined by interaction between factor VII genotype and plasma triglyceride concentration. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[83]  G. Assmann,et al.  Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[84]  M. Blombäck,et al.  The Role of β-Fibrinogen Genotype in Determining Plasma Fibrinogen Levels in Young Survivors of Myocardial Infarction and Healthy Controls from Sweden , 1993, Thrombosis and Haemostasis.

[85]  T. Meade,et al.  Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study , 1993, The Lancet.

[86]  M. Alessi,et al.  Plasminogen Activator Inhibitor 1 and Atherothrombosis , 1993, Thrombosis and Haemostasis.

[87]  A. Henney,et al.  The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. , 1993, The Journal of biological chemistry.

[88]  B. Dahlbäck,et al.  Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[89]  S. Dawson,et al.  The status of PAI-1 as a risk factor for arterial and thrombotic disease: a review. , 1992, Atherosclerosis.

[90]  J. Cruickshank,et al.  Genetic and environmental determinants of factor VII coagulant activity in ethnic groups at differing risk of coronary heart disease. , 1992, Atherosclerosis.

[91]  W D Dupont,et al.  Analysis of the PvuII restriction fragment-length polymorphism and exon structure of the estrogen receptor gene in breast cancer and peripheral blood. , 1992, Cancer research.

[92]  T. Meade,et al.  A common genetic polymorphism associated with lower coagulation factor VII levels in healthy individuals. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[93]  A. Hamsten,et al.  Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. , 1990, Arteriosclerosis.

[94]  C. Redman,et al.  Regulation of fibrinogen assembly. Transfection of Hep G2 cells with B beta cDNA specifically enhances synthesis of the three component chains of fibrinogen. , 1990, The Journal of biological chemistry.

[95]  S. Thung,et al.  Oestrogen receptor B-region polymorphism and spontaneous abortion in women with breast cancer , 1990, The Lancet.

[96]  R. Aster,et al.  The human platelet alloantigens, PlA1 and PlA2, are associated with a leucine33/proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing. , 1989, The Journal of clinical investigation.

[97]  M. Alessi,et al.  Plasma Plasminogen Activator Inhibitor‐1 in Angina Pectoris: Influence of Plasma Insulin and Acute‐phase Response , 1989, Arteriosclerosis.

[98]  W. McGuire,et al.  Estrogen receptor expression in human breast cancer associated with an estrogen receptor gene restriction fragment length polymorphism. , 1989, Cancer research.

[99]  P. Chambon,et al.  Genomic organization of the human oestrogen receptor gene. , 1988, The EMBO journal.

[100]  D. Lawrence,et al.  The organization of the human-plasminogen-activator-inhibitor-1 gene. Implications on the evolution of the serine-protease inhibitor family. , 1988, European journal of biochemistry.

[101]  E. Davie,et al.  Nucleotide sequence of the gene for human prothrombin. , 1987, Biochemistry.

[102]  F. Grant,et al.  Nucleotide sequence of the gene coding for human factor VII, a vitamin K-dependent protein participating in blood coagulation. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[103]  P. Vague,et al.  Relationships between plasma insulin triglyceride, body mass index, and plasminogen activator inhibitor 1. , 1987, Diabete & metabolisme.

[104]  S. Thompson,et al.  HAEMOSTATIC FUNCTION AND ISCHAEMIC HEART DISEASE: PRINCIPAL RESULTS OF THE NORTHWICK PARK HEART STUDY , 1986, The Lancet.

[105]  M. Blombäck,et al.  Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. , 1985, The New England journal of medicine.